These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 26537534)

  • 1. Guidelines for good pharmacoepidemiology practice (GPP).
    Public Policy Committee, International Society of Pharmacoepidemiology
    Pharmacoepidemiol Drug Saf; 2016 Jan; 25(1):2-10. PubMed ID: 26537534
    [No Abstract]   [Full Text] [Related]  

  • 2. Guidelines for good pharmacoepidemiology practices (GPP).
    Epstein M;
    Pharmacoepidemiol Drug Saf; 2005 Aug; 14(8):589-95. PubMed ID: 15918159
    [No Abstract]   [Full Text] [Related]  

  • 3. Guidelines for good pharmacoepidemiology practices (GPP).
    ISPE
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):200-8. PubMed ID: 17868186
    [No Abstract]   [Full Text] [Related]  

  • 4. [Developing process of guide on methodological standards in pharmacoepidemiology (T/CPHARMA 002-2019)].
    Xu Y; Ding CY; Zhuo L; Zhan SY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Oct; 40(10):1186-1190. PubMed ID: 31658514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The case-crossover and case-time-control designs in pharmacoepidemiology.
    Donnan PT; Wang J
    Pharmacoepidemiol Drug Saf; 2001 May; 10(3):259-62. PubMed ID: 11501340
    [No Abstract]   [Full Text] [Related]  

  • 6. Methods in pharmacoepidemiology: a review of statistical analyses and data reporting in pediatric drug utilization studies.
    Sequi M; Campi R; Clavenna A; Bonati M
    Eur J Clin Pharmacol; 2013 Mar; 69(3):599-604. PubMed ID: 22832725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On Comparison of Clustering Methods for Pharmacoepidemiological Data.
    Feuillet F; Bellanger L; Hardouin JB; Victorri-Vigneau C; Sébille V
    J Biopharm Stat; 2015; 25(4):843-56. PubMed ID: 24905478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reuse of data sources to evaluate drug safety signals: When is it appropriate?
    Wang SV; Kulldorff M; Glynn RJ; Gagne JJ; Pottegård A; Rothman KJ; Schneeweiss S; Walker AM
    Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):567-569. PubMed ID: 29701279
    [No Abstract]   [Full Text] [Related]  

  • 9. The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers.
    Mellish L; Karanges EA; Litchfield MJ; Schaffer AL; Blanch B; Daniels BJ; Segrave A; Pearson SA
    BMC Res Notes; 2015 Nov; 8():634. PubMed ID: 26526064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice.
    Weldeselassie YG; Whitaker HJ; Farrington CP
    Epidemiol Infect; 2011 Dec; 139(12):1805-17. PubMed ID: 21849099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biostatistical considerations in pharmacovigilance and pharmacoepidemiology: linking quantitative risk assessment in pre-market licensure application safety data, post-market alert reports and formal epidemiological studies.
    O'Neill RT
    Stat Med; 1998 Aug 15-30; 17(15-16):1851-8; discussion 1859-62. PubMed ID: 9749452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacoepidemiology. Analysis of drug prescription data].
    Gothe H
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Oct; 51(10):1145-54. PubMed ID: 18985408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoepidemiology and Drug Safety's special issue on validation studies.
    Chun DS; Lund JL; Stürmer T
    Pharmacoepidemiol Drug Saf; 2019 Feb; 28(2):123-125. PubMed ID: 30714240
    [No Abstract]   [Full Text] [Related]  

  • 14. Data handling, statistical computing, and archiving.
    Ranstam J
    Acta Radiol; 2008 Dec; 49(10):1137-9. PubMed ID: 18608011
    [No Abstract]   [Full Text] [Related]  

  • 15. Brief discussion on sampling variability in 1:1 propensity score matching without replacement.
    Ripollone JE; Huybrechts KF; Rothman KJ; Ferguson RE; Franklin JM
    Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1194-1197. PubMed ID: 32939910
    [No Abstract]   [Full Text] [Related]  

  • 16. Epidemiologic studies of adverse effects of anti-retroviral drugs: how well is statistical power reported.
    Halpern SD; Barton TD; Gross R; Hennessy S; Berlin JA; Strom BL
    Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):155-61. PubMed ID: 15624138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Translation and introduction of Guide to Methodological Standards in Pharmacoepidemiology].
    Tian F; Liao X; Xie YM
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2949-57. PubMed ID: 24471310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ongoing progress in research on drug exposure and adverse events.
    Knottnerus JA; Tugwell P
    J Clin Epidemiol; 2012 Oct; 65(10):1029-30. PubMed ID: 22910535
    [No Abstract]   [Full Text] [Related]  

  • 19. Generating and confirming hypotheses.
    Gould AL
    Pharmacoepidemiol Drug Saf; 2010 May; 19(5):533-6. PubMed ID: 20437460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of health care databases in pharmacoepidemiology.
    Hennessy S
    Basic Clin Pharmacol Toxicol; 2006 Mar; 98(3):311-3. PubMed ID: 16611207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.